Bavarian Nordic
Clinical trials sponsored by Bavarian Nordic, explained in plain language.
-
Mpox vaccine gets a production upgrade: new cell recipe under trial
⭐️ VACCINE ⭐️ OngoingThis study tests whether the MVA-BN mpox vaccine (Jynneos) works as well when made in quail cells instead of chicken cells. About 970 healthy adults aged 18 to 49 will receive two doses four weeks apart. Researchers will compare immune responses and side effects between the two v…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
Mpox vaccine trial expands to children: a step toward broader protection
⭐️ VACCINE ⭐️ OngoingThis study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:59 UTC
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
⭐️ VACCINE ⭐️ OngoingThis Phase 2 trial tests a new vaccine called MVA-BN-WEV to prevent two types of equine encephalitis (Eastern and Venezuelan), which are rare but serious brain infections spread by mosquitoes. The study involves 411 healthy adults aged 18-50 and aims to find the best dose and dos…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC